HYdroxychloroquine to Improve Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) Protocol: A Multinational Randomized Controlled Trial of Hydroxychloroquine versus Placebo in Addition to Standard Treatment in Pregnant Women with Antiphospholipid Syndrome or Antibodies
This study aims to assess pregnancy outcome in women with aPL treated with HCQ versus placebo in addition to standard treatment. The HYdroxychloroquine to improve Pregnancy outcome in women with AnTIphospholipid Antibodies (HYPATIA) study is a phase IV multicenter RCT, in which pregnant women with persistent aPL will receive either HCQ or placebo in addition to their usual medication. The primary endpoint is a composite of aPL-related adverse pregnancy outcomes: one or more pregnancy loss(es) (either < 10 or > 10 weeks of gestation) and premature birth before 34 weeks due to any of the following preeclampsia, eclampsia, or recognized features of placental insufficiency. The HYPATIA study is expected to provide evidence on the effect of HCQ in pregnant women with persistent aPL. [...] Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.Article in Thieme eJournals: Table of contents | Abstract | Full text
Source: Seminars in Thrombosis and Hemostasis - Category: Hematology Authors: Schreiber, Karen Breen, Karen Cohen, Hannah Jacobsen, Soren Middeldorp, Saskia Pavord, Sue Regan, Lesley Roccatello, Dario Robinson, Susan E. Sciascia, Savino Seed, Paul T. Watkins, Linda Hunt, Beverley J. Tags: Review Article Source Type: research
More News: Antiphospholipid Syndrome | Aspirin | Hematology | Hughes Syndrome | Hydroxychloroquine | Liver | OBGYN | Pre-eclampsia | Pregnancy | Premature Birth | Study | Thrombosis | Urology & Nephrology | Women